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Abstract: Background and Aims: The mechanisms of interindividual variation of lipid regulation by
statins, such as the low-density lipoprotein cholesterol (LDL) lowering effects, are not fully understood
yet. Here, we used a gut microbiota depleted mouse model to investigate the relation between
the gut microbiota and the regulatory property of atorvastatin on blood lipids. Methods: Mice
(C57BL/6) with intact gut microbiota or antibiotic induced abiotic mice (ABS) were put on standard
chow diet (SCD) or high fat diet (HFD) for six weeks. Atorvastatin (10 mg/kg body weight/day)
or a control vehicle were applied per gavage for the last four weeks of dietary treatment. Blood
lipids including total cholesterol, very low-density lipoprotein, low-density lipoprotein, high-density
lipoprotein and sphingolipids were measured to probe microbiota-dependent effects of atorvastatin.
The expression of genes involved in hepatic and intestinal cholesterol metabolism was analyzed with
qRT-PCR. The alteration of the microbiota profile was examined using 16S rRNA qPCR in mice with
intact gut microbiota. Results: HFD feeding significantly increased total blood cholesterol and LDL
levels, as compared to SCD in both mice with intact and depleted gut microbiota. The cholesterol
lowering effect of atorvastatin was significantly attenuated in mice with depleted gut microbiota.
Moreover, we observed a global shift in the abundance of several sphingolipids upon atorvastatin
treatment which was absent in gut microbiota depleted mice. The regulatory effect of atorvastatin on
the expression of distinct hepatic and intestinal cholesterol-regulating genes, including Ldlr, Srebp2
and Npc1l1 was altered upon depletion of gut microbiota. In response to HFD feeding, the relative
abundance of the bacterial phyla Bacteroidetes decreased, while the abundance of Firmicutes increased.
The altered ratio between Firmicutes to Bacteroidetes was partly reversed in HFD fed mice treated
with atorvastatin. Conclusions: Our findings support a regulatory impact of atorvastatin on the gut
microbial profile and, in turn, demonstrate a crucial role of the gut microbiome for atorvastatin-related
effects on blood lipids. These results provide novel insights into potential microbiota-dependent
mechanisms of lipid regulation by statins, which may account for variable response to statin treatment.
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1. Introduction
Statins are the most prescribed metabolic drugs for the treatment of patients with
hypercholesterolemia with proven beneficial effects on patients’ prognosis both for primary [1]
and secondary [2] prevention.
As inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) statins reduce the
synthesis of cholesterol and increase the expression of low-density lipoprotein receptor (LDLR) resulting
in decreased plasma LDL cholesterol (LDL) levels [3]. Accumulating evidence also suggests that
statins mediate cholesterol removal via feces. In particular, atorvastatin mainly promotes cholesterol
removal via the transintestinal cholesterol excretion pathway [4]. Although the modes of action of
statins have been intensively investigated, there is still uncertainty about the mechanisms underlying
interindividual variations in their regulatory property on plasma lipids, and in particular, their LDL
lowering magnitude.
Increasing evidence implicate that metabolic drugs modulate both the composition and metabolic
activity of the gut microbiota. This interaction is proposed to contribute to therapeutic effects of
metabolic drugs, such as metformin [5], suggesting a relation between gut microbiota plasticity and
individual response to pharmacotherapies. Thus, it is conceivable that the interindividual variability
of therapeutic effects may depend on the composition of the gut microbiota, as well as microbe-related
metabolites and their alteration upon treatment with subsequent regulatory effects on statin-mediated
intestinal or hepatic regulation of cholesterol metabolism.
Here, we studied the influence of the gut microbiota on the modulatory effect of atorvastatin on
the blood lipid profile in hypercholesterolemic mice with antibiotics-induced (ABS) depletion of the
gut microbiota as compared to mice with intact gut microbiota (conventional, CONV). Additionally,
the alteration of the gut microbiota composition was investigated upon treatment with atorvastatin.
The results of our study may shed further insight into the role of the gut microbiome for the
lipid-regulating property of statins and help to provide novel gut microbiota related strategies to
optimize the cholesterol-lowering effects of statins.
2. Methods
2.1. Mouse Experiments
All animals were bred, raised and housed in the facilities of the “Forschungseinrichtungen
für Experimentelle Medizin” (FEM, Charité—University Medicine Berlin, Germany) under specific
pathogen-free (SPF) conditions with a 12 h-12 h day-night rhythm and unlimited access to food and
water. Adult (16 weeks of age) C57BL/6J mice (Charles River) were placed on standard chow (SCD,
Crude fat 4.1%, Cholesterol 14 mg/kg; E15000) or high-fat diet (HFD, Crude fat 34.6%, Cholesterol
290 mg/kg; E15741) (Ssniff, Soest, Germany) for 6 weeks prior to lipidome analysis. At the end
of the 6 week-period mice were sacrified for collection of blood and organs (Figure 1). Mouse
experiments were approved by the research advisory committee and permitted by LAGeSo (Landesamt
für Gesundheit und Soziales Berlin, G0295/16).
2.2. Generation of Secondary Abiotic Mice
Secondary abiotic mice were generated through quintuple antibiotic treatment (+ABS) for 6 weeks
via drinking water as shown previously [6]. In brief, mice were transferred to sterile cages and treated
with a mix of ampicillin plus sulbactam (1 g/L), vancomycin (500 mg/L), ciprofloxacin (200 mg/L),
imipenem (250 mg/L) and metronidazole (1 g/L) in autoclaved tap water (ad libitum). The intestinal
colonization status of the mice was controlled once a week by highly sensitive cultural analysis of fecal
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samples. As early as three weeks of broad-spectrum antibiotic treatment, quality controls indicated
virtually complete eradication of the intestinal microbiota, as demonstrated by negative results derived
from both, culture and molecular detection of bacteria, using real-time PCR targeting of bacterial
16S rRNA genes. To avoid contaminations, mice were continuously kept in a sterile environment
(autoclaved food and drinking water, sterile filtered antibiotic cocktail) and handled under strict
aseptic conditions.




Figure 1. Experimental design. Secondary abiotic mice were generated by quintuple antibiotic 
treatment (+ABS). After pretreatment with or without antibiotics both ABS and CONV mice were 
exposed to either standard chow diet or high-fat diet. Two weeks after initiating the diet ABS and 
CONV mice were treated, either with control vehicle or atorvastatin for 4 weeks. 
2.2. Generation of Secondary Abiotic Mice 
Secondary abiotic mice were generated through quintuple antibiotic treatment (+ABS) for 6 
weeks via drinking water as shown previously [6]. In brief, mice were transferred to sterile cages and 
treated with a mix of ampicillin plus sulbactam (1 g/L), vancomycin (500 mg/L), ciprofloxacin (200 
mg/L), imipenem (250 mg/L) and metronidazole (1 g/L) in autoclaved tap water (ad libitum). The 
intestinal colonization status of the mice was controlled once a week by highly sensitive cultural 
analysis of fecal samples. As early as three weeks of broad-spectrum antibiotic treatment, quality 
controls indicated virtually complete eradication of the intestinal microbiota, as demonstrated by 
negative results derived from both, culture and molecular detection of bacteria, using real-time PCR 
targeting of bacterial 16S rRNA genes. To avoid contaminations, mice were continuously kept in a 
sterile environment (autoclaved food and drinking water, sterile filtered antibiotic cocktail) and 
handled under strict aseptic conditions. 
2.3. Molecular Analysis of Intestinal Microbiota 
Major bacterial groups present in the murine gut microbiota were quantified by assessing the 
quantity of 16S rRNA gene copies per ng DNA applying quantitative real-time polymerase chain 
reaction with species-, genera- or group-specific 16S rRNA gene primers (Tib MolBiol, Berlin, 
Germany) (Supplementary Table S1). 
Briefly, fecal samples were collected and preserved for further analysis with nitrogen. For DNA 
extraction the samples were suspended in PBS and centrifuged (16.000× g/10 min/4 °C). The probes 
were resuspended in 0.5 mL lysis buffer (500 mM Tris (pH 9.0), 20 mM EDTA, 10 mM NaCl, 1% SDS) 
and incubated with proteinase K (2 mg/mL; Sigma-Aldrich, St. Louis, MO, USA) for 1 h at 56 °C. After 
bead beating, total DNA was isolated by phenol extraction and quantified by using Quant-iT 
PicoGreen reagent (InvitrogenTM, Carlsbad, CA, USA) and adjusted to 1 ng per µL [6,7]. 
2.4. Histology 
Following sacrifice, organs were immediately embedded in tissue freezing medium (Leica) and 
frozen on dry ice. Tissues were stored at −80 °C until further use. Thin Sections (5 um) of the liver 
were prepared on glass slides (Thermo Scientific, Super frost PLUS) using the Cryostat Microtome 
(Microm HM 560). Tissues were then stained with Oil Red O and counterstained with haematoxylin 
following standard staining protocols. Images were analyzed with ImageJ Software. Small intestinal 
tissues were fixed in paraffin. Sections (1–2 µm) were then stained with a polyclonal rabbit antibody 
(Novus Biologicals, #NB400-127) for detection of Niemann-Pick type C1 Like-1 protein. 
2.5. qRT-PCR and Western Blot 
Figure 1. Experimental design. Secondary abiotic mice were generated by quintuple antibiotic
treatment (+ABS). After pretreatment with or without antibiotics both ABS and CONV mice were
exposed to either standard chow diet or high-fat diet. Two weeks after initiating the diet ABS and
CONV mice were treated, either with control vehicle or atorvastatin for 4 weeks.
2.3. Molecular Analysis of Intestinal Microbiota
Major bacterial groups present in the murine gut microbiota were quantified by assessing the
quantity of 16S rRNA gene copies per ng DNA applying quantitative real-time polymerase chain
reaction with species-, genera- or group-specific 16S rRNA gene primers (Tib MolBiol, Berlin, Germany)
(Supplementary Table S1).
Briefly, fecal samples were collected and preserved for further analysis with nitrogen. For DNA
extraction the sample wer suspended in PBS and centrifuged (16.000× g/10 min/4 ◦C). The probes
were resuspende in 0.5 mL lysis buffer (500 mM Tris (pH 9.0), 20 mM EDTA, 10 mM NaCl, 1% SDS)
and incubated with proteinase K (2 mg/mL; Sigma-Aldrich, St. Louis, MO, USA) for 1 h at 56 ◦C.
After bead beating, total DNA was isolated by phenol extraction and quantified by using Quant-iT
PicoGreen reagent (InvitrogenTM, Carlsbad, CA, USA) and adjusted to 1 ng per µL [6,7].
2.4. Histology
Following sacrifice, o gans were imm diately embedded in tissue freezing medium (Leica) and
frozen on dry ice. Tissues were stored at −80 ◦C until further use. Thin Sections (5 um) of the liver
were prepared on glass slides (Thermo Scientific, Super frost PLUS) using the Cryostat Microtome
(Microm HM 560). Tissues were then stained with Oil Red O and counterstained with haematoxylin
following standard staining protocols. Images were analyzed with ImageJ Software. Small intestinal
tissues re fixed in paraffin. Sect ons (1–2 µ ) were then stained with a polyclonal rabbit antibody
(Novus Biologic ls, #NB400-127) for detection of Niemann-Pick type C1 Like-1 protein.
2.5. qRT-PCR and Western Blot
Total RNA from liver and ileum was isolated with TRIzol reagent (Invitrogen™; 15596026)
following manufacturer’s instructions and quantified using absorbance measurements on a NanoDrop
(Thermo Scientific™, Waltham, MA, USA; ND-2000). Enzymatic DNA digestion was performed
on total RNA from both ti sues using RNase-free DNase I, (1 U/µg; Thermo Scient fic™; EN0251).
Total RNA (1.5 µg) was used for the reverse transcription of hepatic RNA using the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems™, Foster City, CA, USA; 4368814) and 0.5 µg of
total RNA for intestinal tissue using the High-Capacity RNA-to-cDNA Kit (Applied Biosystems™;
4388950). Relative mRNA expression of the hepatic (Cyp7a1, Fxr, Hmgcr, Ldlr, Pcsk9, Srebp2) and
intestinal genes (Abca1, Abcg5, Acat2, Asbt, Npc1l1, Srb1) and Gapdh as reference gene was analyzed
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using the following TaqMan Gene Expression Assays as primers (Applied Biosystems™; 4351372)
(Supplementary Table S2).
Relative expression (triple determination) was examined by TaqMan Gene Expression Master Mix
(Applied Biosystems™; 4369542) following the manufacturer´s instructions.
Isolation of total cellular proteins and protein expression levels by Western blotting using SDS-Page
were performed according to standard protocols [8]. Rabbit polyclonal anti-LDLR (1:500; Abcam,
Cambridge, UK) and anti-SREBP2 antibodies (1:500; NovusBio, Littleton, CO, USA) were used
as primary antibodies and equal protein loading was verified by reprobing the membrane with a
mouse monoclonal anti-GAPDH antibody (1:10,000, Merck, Kenilworth, NJ, USA). As secondary
antibodies polyclonal goat anti-mouse and anti-rabbit antibodies were used (1:10,000, SouthernBiotech,
Birmingham, AL, USA).
2.6. Metabolite Profiling and Lipoprotein Separation
For Metabolite profiling, all plasma samples were shipped on dry ice and analyzed at the
Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany, using a
targeted metabolomics kit (MxP®Quant 500 kit: BIOCRATES Life Sciences AG, Innsbruck, Austria).
This approach allows simultaneous absolute quantification of up to 630 metabolites covering 26
compound classes including 14 small molecule and 12 lipid classes using a combination of liquid
chromatography (Agilent 1290 Infinity II LC, Santa Clara, CA, USA) and mass spectrometry (AB
SCIEX 5500 QTrap™ mass spectrometer; AB SCIEX, Darmstadt, Germany). After normalization
and pre-processing of the data, using MetIDQ™ software (Biocrates, Innsbruck, Austria) for peak
integration and calculation of metabolite concentrations, 15 sphingolipids, distinct acylcarnitines and
bile acids were employed for further investigation in the present study, whereas the unmentioned
metabolites are documented in the supplemental Table S3.
Fast performance liquid chromatography (FPLC) was used for lipoprotein separation by means of
two Superose 6 columns connected in series.
2.7. Statistical Analyses
Database management and statistical analyses were performed with PRISM version 8.2.0
(GraphPad Software Inc., San Diego, CA, USA) and IBM SPSS Statistics 25 (IBM, Armonk, NY, USA).
Grubbs’test was performed to identify and exclude outliers. Continuous data were subjected to
the Kolmogorov–Smirnov- and Shapiro–Wilk-test to determine their distribution and were expressed
as mean ± standard error of the mean (SEM). Comparison of means of normally distributed data
was performed by independent t-test and Mann-Whitney U-test was used if data were not normally
distributed. Significance was assumed at a two-sided p-value ≤ 0.05.
3. Results
3.1. Differences in Diet-Induced Weight Gain in Conventionally Raised and Abiotic Mice
After diet initiation, weight change was monitored daily. As illustrated in Figure 2A, HFD induced
significant weight gain in CONV mice (CONV+SCD vs. CONV+HFD: 98.5 ± 0.5 (% of baseline)
vs. 114.7 ± 5.2 (% of baseline), p = 0.025), which was not affected by treatment with atorvastatin
(CONV+HFD vs. CONV+HFD+Ator: 114.7 ± 5.2 (% of baseline) vs. 112.2 ± 4.6 (% of baseline),
p = 0.76). Interestingly, this diet-induced weight gain was not observed in ABS mice (ABS+SCD vs.
ABS+HFD: 97.1 ± 0.8 (% of baseline) versus 104.1 ± 4.6 (% of baseline), p = 0.08) (Figure 2B). This is in
line with previously reported resistance to diet-induced obesity in germ-free mice [9]. In abiotic mice
treatment with atorvastatin even significantly increased body weight (ABS+SCD vs. ABS+HFD+Ator:
97.1 ± 0.8 (% of baseline) vs. 105.2 ± 2.1 (% of baseline), p = 0.001) (Figure 2).
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3.2. Effect of Atorvastatin on Cholesterol and Lipoprotein Levels in Conventionally Raised and Abiotic Mice
In CONV, as well as in ABS mice, HFD significantly increased serum levels of total cholesterol (TC)
(Figure 3A–F). Similarly, levels of very low-density lipoprotein (VLDL), LDL and high-density
lipoprotein (HDL) were significantly elevated upon HFD. While, treatment with atorvastatin
significantly reduced levels of TC, VLDL, LDL and HDL in conventionally raised mice, it failed
to show a significant effect on respective lipids in mice with depleted gut microbiota. Moreover, HFD
induced hepatic fat deposition was reduced upon atorvastatin treatment in CONV mice while fatty
liver damage in ABS mice remained high (Figure 3G).
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3.3. Regulatory Effect of Atorvastatin on Blood Lipidome in Mice with Intact and Depleted Gut Microbiota
under High Fat Diet
To further investigate the impact of the gut microbiome on lipid-regulatory properties of
atorvastatin we compared changes of a broad range of lipids including sphingolipids, ceramides,
glycerophospholipids, triacylglycerols and glycosylceramides in HFD fed CONV and ABS mice with
atorvastatin. The most striking difference between CONV and ABS mice was observed for sphingolipids.
While, in both CONV and ABS mice the serum levels of many sphingolipids significantly increased
upon HFD, treatment with atorvastatin prevented the increase in sphingolipid levels only in CONV
mice, whereas sphingolipid levels remained largely unaffected upon atorvastatin treatment in ABS
mice (Figure 4). Analyses of changes in the serum levels of glycerophospholipids, triacylglycerols,
ceramides and glycosylceramides are provided in the supplementary table. As for these lipids, only
minor differences were found between atorvastatin treated CONV-HFD and ABS-HFD mice (Table S3).
3.4. Atorvastatin Alters the of Gut Microbiota Composition
In order to investigate how HFD alters the composition of gut microbiota and whether this
alteration may be affected by treatment with atorvastatin, we collected fecal samples of all mice from
the respective groups at the end of the diet and treatment period (Figure 1). As depicted in Figure 5,
an increase in the absolute (A); and relative (B); abundance of phylum Firmicutes was found after HFD,
as compared to SCD, while the absolute and relative abundance of bacterial phylum Bacteroidetes was
decreased. Importantly, the increased ratio between Firmicutes to Bacteroidetes was partly reversed in
HFD fed mice upon treatment with atorvastatin. Analysis of distinct bacterial groups displayed an
increase in fecal gene copies of Lactobacillus group and Enterococcus genus by HFD, which was reversed
to control levels upon treatment with atorvastatin (Figure 5D,E). Importantly Bifidobaterium genus was
scarcely detected in SCD fed mice but increased in HFD. This augmentation was completely prevented
in HFD fed mice treated with atorvastatin. Clostridium coccoides group was significantly decreased in
mice upon HFD and increased even above control levels in response to treatment with atorvastatin.
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Figure 5. Analysis of intestinal microbiota. (A,B): Alterations of main intestinal bacterial phyla in 
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3.5. Regulatory Effect of Atorvastatin on Hepatic and Intestinal Genes Involved in Cholesterol Metabolism in 
Mice with Intact and Depleted Gut Microbiome 
Expression analysis of genes involved in cholesterol metabolism in the liver (Figure 6A) 
displayed a significant increase of mRNA levels of the bile acid-synthetic enzyme cholesterol 7α-
hydrolase (Cyp7a1) in both CONV and ABS mice (CONV+HFD vs. CONV+HFD+Ator: 71.2 ± 16.6% 
vs. 147.2 ± 25.1%, p = 0.036; ABS+HFD vs. ABS+HFD+Ator: 60.7 ± 16.4% vs. 256.4 ± 58.0%, p = 0.012) 
indicating gut microbiota-independent regulatory property of atorvastatin on bile acid homeostasis. 
However, the mRNA expression of sterol regulatory element-binding protein 2 (Srebp2) (CONV+SCD 
vs. CONV+HFD+Ator: 100.0 ± 5.0% vs. 192.2 ± 36.4%, p = 0.037; ABS+SCD vs. ABS+HFD+Ator: 313.6 
± 29.3% vs. 117.6 ± 30.6%, p = 0.002), the major transcription factor regulating the cholesterol 
homoeostasis, LDL-receptor (Ldlr) (CONV+SCD vs. CONV+HFD+Ator: 100.0 ± 11.8% vs. 136.5 ± 
13.7%, p = 0.078; ABS+SCD vs. ABS+HFD+Ator: 175.9 ± 13.1% vs. 96.3 ± 21.8%, p = 0.008) and of 
proprotein convertase subtilisin kexin typ 9 (Pcsk9) (CONV+SCD vs. CONV+HFD+Ator: 100.0 ± 
14.4% vs. 101.2 ± 13.9%, p = 0.955; ABS+SCD vs. ABS+HFD+Ator: 28.8 ± 3.4% vs. 131.1 ± 53.0%, p = 
0.03) were differently regulated by atorvastatin in ABS mice as compared to CONV mice. A similar 
trend was also observed on protein level (Figure 6B) (SREBP2: CONV+HFD vs. CONV+HFD+Ator: 
169.8 ± 39.0% (relative protein expression) vs. 213.7 ± 15.5%, p = 0.39; ABS+HFD vs. ABS+HFD+Ator: 
136.8 ± 31.5% vs. 124.3 ± 33.3%, p = 0.81; LDL-R: CONV+HFD vs. CONV+HFD+Ator: 121.4 ± 27.7% vs. 
135.7 ± 27.3%, p = 0.76; ABS+HFD vs. ABS+HFD+Ator: 178.9± 19.9% vs. 71.2 ± 8.2%, p = 0.002). In ileum, 
mRNA expression of most cholesterol regulating genes displayed a similar trend in both HFD fed 
. l sis f l . (A,B): lterations of i i t ti l t ri l l
a the effects of Ator treatment (n = 15). (C–L): Analysi of 16S rRNA gen copies of
dist nct bacterial groups (n = 15). Erro bars indicate SEM. * = p < 0. 5, ** = p < 0.01; * =
3.5. Regulatory Effect of Atorvastatin on Hepatic and Intestinal Genes Involved in Cholesterol Metabolism in
Mice with Intact and Depleted Gut Microbiome
Expression analysis of genes involved in cholesterol metabolism in the liver (Figure 6A) displayed
a significant increase of mRNA levels of the bile acid-synthetic enzyme cholesterol 7α-hydrolase
(Cyp7a1) in both CONV and ABS mice (CONV+HFD vs. CONV+HFD+Ator: 71.2 ± 16.6% vs.
147.2 ± 25.1%, p = 0.036; ABS+HFD vs. ABS+HFD+Ator: 60.7 ± 16.4% vs. 256.4 ± 58.0%,
p = 0.012) indicating gut microbiota-independent regulatory property of atorvastatin on bile acid
homeostasis. However, the mRNA expression of sterol regulatory element-binding protein 2 (Srebp2)
(CONV+SCD vs. CONV+HFD+Ator: 100.0 ± 5.0% vs. 192.2 ± 36.4%, p = 0.037; ABS+SCD vs.
ABS+HFD+Ator: 313.6 ± 29.3% vs. 117.6 ± 30.6%, p = 0.002), the major transcription factor regulating
the cholesterol homoeostasis, LDL-receptor (Ldlr) (CONV+SCD vs. CONV+HFD+Ator: 100.0 ± 11.8%
vs. 136.5 ± 13.7%, p = 0.078; ABS+SCD vs. ABS+HFD+Ator: 175.9 ± 13.1% vs. 96.3 ± 21.8%, p = 0.008)
and of proprotein convertase subtilisin kexin typ 9 (Pcsk9) (CONV+SCD vs. CONV+HFD+Ator:
100.0± 14.4% vs. 101.2± 13.9%, p = 0.955; ABS+SCD vs. ABS+HFD+Ator: 28.8± 3.4% vs. 131.1± 53.0%,
p = 0.03) were differently regulated by atorvastatin in ABS mice as compared to CONV mice. A similar
trend was also observed on protein level (Figure 6B) (SREBP2: CONV+HFD vs. CONV+HFD+Ator:
169.8 ± 39.0% (relative protein expression) vs. 213.7 ± 15.5%, p = 0.39; ABS+HFD vs. ABS+HFD+Ator:
136.8 ± 31.5% vs. 124.3 ± 33.3%, p = 0.81; LDL-R: CONV+HFD vs. CONV+HFD+Ator: 121.4 ± 27.7%
vs. 135.7 ± 27.3%, p = 0.76; ABS+HFD vs. ABS+HFD+Ator: 178.9± 19.9% vs. 71.2 ± 8.2%, p = 0.002).
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In ileum, mRNA expression of most cholesterol regulating genes displayed a similar trend in both HFD
fed CONV and ABS mice with similar alteration upon atorvastatin treatment in both groups (Figure 7).
However, mRNA expression of Niemann-Pick C1-like protein 1 (Npc1l1), the major transporter
protein regulating intestinal cholesterol absorption was significantly increased by atorvastatin in mice
with depleted gut microbiota whereas in CONV mice atorvastatin tended to reduce its expression
(CONV+HFD vs. CONV+HFD+Ator: 86.5 ± 10.6% vs. 59.0 ± 11.7%, p = 0.12; ABS+HFD vs.
ABS+HFD+Ator: 80.1 ± 13.5% vs. 119.8 ± 16.8%, p = 0.1; CONV+HFD+Ator vs. ABS+HFD+Ator:
59.0 ± 11.7% vs. 119.8 ± 16.8%, p = 0.018) suggesting gut microbiota-dependent inverse regulation
of intestinal cholesterol absorption by atorvastatin. An overview on the role of the key regulating
genes involved in hepatic and intestinal cholesterol metabolism and altered gene expression upon
atorvastatin treatment in CONV and ABS mice is provided in Figure 8.
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Figure 6. Hepatic genes and proteins. (A–F): Hepatic expression of genes involved in cholesterol
metabolism and their alteration upon HFD + atorvastatin treatment in CONV (n = 15) and ABS (n = 19)
mice. (G–J): Hepatic protein expression of sterol regulatory element-binding protein 2 (Srebp2) and ldl
receptor (Ldlr) gene expression by atorvastatin in ABS (n = 12) mice as compared to CONV (n = 12)
mice. The protein levels of srebp2 and ldlr were further evaluated by Western Blot (B). Error bars
indicate SEM. * = p < 0.05, ** = p < 0.01; *** = p < 0.001.
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4. Discussion
The present study is the first to explore the implication of the gut-microbiome for the lipid
modulatory effect of atorvastatin in a gut microbiota depleted mouse model and provides several
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important observations: (i) Atorvastatin partly reverses the shift in gut microbiota composition induced
by high-fat diet, (ii) the lipid lowering effect of atorvastatin is significantly attenuated in mice with
depleted gut microbiota, and (iii) depletion of gut microbiota significantly alters the atorvastatin-related
effects on distinct hepatic and intestinal genes involved in cholesterol metabolism.
Low response to statin therapy may impede proper control of hypercholesterolemia for optimized
cardiovascular disease prevention. However, mechanisms of inter-individual variations, in response to
statin therapy, still remain unclear [10]. We hypothesized that the magnitude of statin response may at
least be partly related to the gut microbiome, given recent advances in understanding the implication
of the gut microbiome and its metabolites for the host’s physiology and metabolism, as well as its
interaction with pharmaceutic actions of metabolic drugs.
Accumulating evidence indicates that the gut microbiome and microbiota-dependent metabolites
modulate the effect of metabolic drugs [11]. For example, the antidiabetic effects of metformin have
been identified to be related to the microbiota. In particular, metformin has been reported to alter gut
microbiota composition in humans [12], specifically to reduce the abundance of Bacteroides fragilis in the
gut, which leads to an increase in antagonists of the farnesoid X receptor (FXR), and ultimately results
in improved insulin sensitivity [13]. Another recent study observed significant changes in Escherichia
and Intestinibacter abundance in metformin-treated patients [5], which was also found in another
cross-sectional study comparing metformin-treated and untreated patients with type II diabetes [11].
Findings from these studies point to a bi-directional relation between the gut microbiome and drug
action: While metformin alters the composition of the gut microbiome, either directly or indirectly,
the gut bacterial profile also impacts on the anti-diabetic effects of metformin.
In view of these findings, we aimed to explore whether a cross talk between the gut microbiome and
statin therapy may also modulate cholesterol lowering effects of statins. Indeed, we observed reduced
cholesterol lowering capacity of atorvastatin in mice with depleted gut microbiome, suggesting
the involvement of bacterial pathways in cholesterol regulating actions of atorvastatin. Notably,
atorvastatin-related effects on two metabolic genes involved in hepatic cholesterol homeostasis, Ldlr and
Srebp2, were partly different upon gut microbiome depletion, suggesting that gut microbiota-related
circuits are involved in classical statin-regulated hepatic cholesterol metabolism. Moreover, the
expression of Npc1l1, the major transporter protein regulating intestinal cholesterol absorption [14]
increased by atorvastatin in mice, with depleted gut microbiome. It tended to decrease upon atorvastatin
treatment in conventional mice as compared to abiotic mice, suggesting different cholesterol absorption
capacity in the small intestine between conventional and abiotic mice. These differences may as a net
effect ultimately lead to attenuated cholesterol regulating property of atorvastatin in abiotic mice as
compared to conventional mice.
Importantly, a broader analysis of the lipidomic profile revealed that distinct lipid classes which
were decreased by atorvastatin in conventionally raised mice were unaltered upon atorvastatin in gut
microbiome depleted mice. In particular, several sphingolipids were no longer different following
atorvastatin treatment in abiotic mice. These observations may have additional implication for
atheroprotective features of statins given the potential pro-atherogenic effects of sphingolipids and
ceramides [15].
Importantly, atorvastatin treated hypercholesterolemic mice demonstrated a shift in the
composition of the gut microbiota. While, a high-fat diet decreased the relative abundance of
the bacterial phylum Bacteroidetes and increased the abundance of Firmicutes as compared to standard
chow diet, the ratio between Firmicutes to Bacteroidetes was reversed towards control conditions upon
atorvastatin treatment, although not fully restored. This reorganization of the gut microbial community
may drive intestinal cholesterol-regulating circuits. Indeed, several strains belonging to Bacteroidetes
have been identified to possess cholesterol-reducing activity by converting cholesterol to the saturated
product coprostanol [16].
A recent study examining the effect of simvastatin on the gut-microbiome and metabolome
in mice observed a profound shift in microbiota-related metabolites. In particular, host serum
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levels of distinct acrylcarnitines were significantly reduced, such as hydroxytetradecenoylcarnitine,
octadecanoylcarnitine and malonylcarnitine+3 hydroxybutyrylcarnitine, which are considered to
promote obesity and metabolic diseases [17]. Another metabolic pathway that may link the gut
microbiome with the magnitude of statin effect are secondary bile acids [18]. In particular, specific
primary and secondary bile metabolites that have been correlated with a lipid lowering response to
statins, include taurocholic acid, glycholic acid, taurochenodeoxycholic acid, glychoneodeoxycholic
acid and glycoursodeoxycholic acid, suggesting a modulatory effect of the gut microbiome on the lipid
lowering capability of statins based on their regulation of bile metabolites.
5. Conclusions
Our findings demonstrate that atorvastatin´s modulatory actions on the lipidome including
LDL lowering effects partly depend on its interaction with the gut microbiome. This cross-talk may
contribute to the inter-individual variation of response to statin therapy depending on the patients’
gut microbial profile. However, additional clinical studies, combining untargeted metabolomics and
metaproteomics, are required to identify distinct microbial pathways that impact on statin effects and
to determine how they interact with the host targets to regulate cholesterol metabolism.
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